Fig. 2From: Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19Length of hospital days in patients in the interventional and observation cohort after propensity-score matchingBack to article page